Literature DB >> 8450498

A novel agonist binding site on nicotinic acetylcholine receptors.

E F Pereira1, M Alkondon, T Tano, N G Castro, M M Fróes-Ferrão, R Rozental, R S Aronstam, A Schrattenholz, A Maelicke, E X Albuquerque.   

Abstract

This report provides evidence that physostigmine (Phy) and benzoquinonium (BZQ) are able to activate nicotinic acetylcholine receptors (nAChRs) through binding site(s) distinct from those of the natural transmitter, ACh. Such findings are in agreement with a second pathway of activation of nAChRs. Receptor activation may be modulated through the novel site, and, consequently, physiological processes involving nicotinic synapses could be controlled. Using patch clamp techniques, single channel currents activated by ACh and anatoxin were recorded from frog interosseal muscle fibers under cell-attached condition and outside-out patches excised from cultured rat hippocampal neurons. Whole cell nicotinic currents were also studied in the cultured neurons. In most of the neurons, nicotinic responses were blocked by the nicotinic antagonists methyllycaconitine (MLA) and alpha-bungarotoxin (alpha-BGT). Evaluation of the effects of Phy and BZQ on the muscle and on the alpha-BGT- and MLA-sensitive neuronal nAChRs demonstrated that both compounds were open channel blockers at these receptors. Furthermore, at low micromolar concentrations, Phy and BZQ activated the nAChRs of all preparations tested, such an effect being unexpectedly resistant to alpha-BGT or MLA. Thus, the nAChRs could be activated via two distinct binding sites: one for ACh and the other for Phy and BZQ. These findings and previous biochemical results led us to suggest that a putative endogenous ligand could bind to the new site and thereby regulate the activation of nAChRs in nicotinic synapses.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8450498     DOI: 10.3109/10799899309073670

Source DB:  PubMed          Journal:  J Recept Res        ISSN: 0197-5110


  5 in total

Review 1.  Cholinergic modulation by opioid receptor ligands: potential application to Alzheimer's disease.

Authors:  William C Motel; Andrew Coop; Christopher W Cunningham
Journal:  Mini Rev Med Chem       Date:  2013-03       Impact factor: 3.862

2.  Galantamine is not a positive allosteric modulator of human α4β2 or α7 nicotinic acetylcholine receptors.

Authors:  Natalia M Kowal; Philip K Ahring; Vivian W Y Liao; Dinesh C Indurti; Benjamin S Harvey; Susan M O'Connor; Mary Chebib; Elin S Olafsdottir; Thomas Balle
Journal:  Br J Pharmacol       Date:  2018-06-07       Impact factor: 8.739

3.  Calcium signalling mediated through α7 and non-α7 nAChR stimulation is differentially regulated in bovine chromaffin cells to induce catecholamine release.

Authors:  Laura del Barrio; Javier Egea; Rafael León; Alejandro Romero; Ana Ruiz; Mayte Montero; Javier Alvarez; Manuela G López
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

4.  A transgenic mouse model reveals fast nicotinic transmission in hippocampal pyramidal neurons.

Authors:  Michael J Grybko; Eu-Teum Hahm; Wesley Perrine; Jason A Parnes; Wallace S Chick; Geeta Sharma; Thomas E Finger; Sukumar Vijayaraghavan
Journal:  Eur J Neurosci       Date:  2011-04-19       Impact factor: 3.386

5.  Blockade of nicotinic responses by physostigmine, tacrine and other cholinesterase inhibitors in rat striatum.

Authors:  P B Clarke; M Reuben; H el-Bizri
Journal:  Br J Pharmacol       Date:  1994-03       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.